Financial Shenanigans

The Forensic Verdict

Tenet's headline FY2024 GAAP profit was structurally distorted, but the company is open about it: a $2.916B pre-tax "Net gains on sales, consolidation and deconsolidation of facilities" sits above the operating income line in the FY2024 income statement, lifting reported operating income by 51% and net income by roughly 6x in a single year before normalizing in FY2025. Underlying cash conversion looks acceptable (3-year CFO/NI 1.53x, 3-year FCF/NI 1.01x), receivables shrank in line with disposed hospitals, and capex/depreciation has finally re-crossed 1.0x. The forensic risks that earn this name a "Watch" — not "Clean" — sit in three places: the unusually permissive operating-income presentation of the divestiture gain, a 2025 short-seller allegation citing an active SEC enforcement matter, and a leadership transition in the accounting function (Principal Accounting Officer change effective May 1, 2026) layered on top of a multi-decade history of fraud settlements. The single data point that would most change this grade is whether the rumored SEC enforcement matter in Tenet's FOIA appeal results in charges, a settlement, or a non-public closure.

Shenanigans Scorecard - 13 categories

Breeding Ground

Tenet sits in a higher-than-average breeding ground for accounting risk, dominated by a long settlement history and management compensation tied to the very metrics under question. None of the 2025-2026 governance signals individually trigger an alarm, but the cluster matters when read together.

The compensation structure is the most consequential breeding-ground signal: long-term equity vests on Adjusted EPS, free cash flow, ROIC and relative TSR, while annual cash incentives reference Adjusted EBITDA and revenue. Each of those metrics is influenced by exactly the items this report examines (gain-on-sale presentation, Conifer cash flow timing, supplemental Medicaid recognition). That alignment is sector-standard but means the company's economic incentives are not neutral on accounting choices.

Earnings Quality

Underlying earnings quality is mixed. The clean side: revenue growth and receivables growth converged in FY2025, supplies and labor cost ratios are improving, and the capex cycle is stepping up rather than down. The unclean side: FY2024 GAAP operating income reported a 14.1 percentage-point margin tailwind that was entirely a $2.916B divestiture gain.

The FY2024 operating-income distortion

The $2,916M FY2024 line item — labeled "Net gains on sales, consolidation and deconsolidation of facilities" — sits inside the operating expense reconciliation and pushes operating income from a normalized ~$3,040M to a reported $5,956M. That presentation is GAAP-consistent for divestitures of a going concern, but it makes the income statement look as though hospital margins doubled in 2024. They did not. Adjusted EBITDA of $4.0B in 2024 versus $4.57B in 2025 is the more honest comparable.

Cash conversion vs reported earnings

Two anomalies stand out. FY2024 net income spiked to $3.2B because of the divestiture gain, while CFO actually fell to $2.05B — the gain is a non-cash accounting event so it does not pass through CFO. FY2025 then shows the inverse: CFO jumped to $3.54B, well above net income of $1.41B, mostly because cash income tax payments dropped $821M after absorbing the FY2024 gain-related tax bill. Across three years the picture normalizes (3Y CFO/NI 1.53x, 3Y FCF/NI 1.01x), but neither single year is a clean read on durable cash earnings.

Receivables vs revenue

This is one of the cleanest earnings-quality tests Tenet passes. Receivables fell 13% in FY2024 because divested hospitals took their AR with them — exactly what disposal accounting predicts. In FY2025 receivables grew only 1.1% versus 3.1% revenue growth, a favorable working-capital read. There is no sign of channel-stuffing or premature revenue recognition at the consolidated level.

Soft assets

Goodwill rose roughly $900M from FY2023 to FY2025 even as the hospital footprint shrank, reflecting USPI's rolling ASC acquisition program. Goodwill plus intangibles is now 42% of total assets — high but consistent with an acquisition-led ambulatory platform strategy. There is no impairment in recent periods. Worth monitoring because USPI multiples paid have stayed stretched in deal markets and an enrollment-driven volume miss could test goodwill assumptions in 2026.

Cash Flow Quality

Cash flow looks healthy but is bracketed by two distortions: a working-capital release as hospitals were sold in 2024, and an upcoming three-year boost from the Conifer transaction starting in 2026.

Working-capital and acquisition-adjusted FCF

After capex and acquisitions, FCF was $2.22B in FY2025, the strongest read in the cycle. But two adjustments shift the run-rate view:

• FY2025 cash taxes were $821M below FY2024 because the FY2024 gain pushed tax payments into that year. Normalize FY2025 cash taxes upward by roughly half of that one-time benefit, and FCF after acquisitions falls toward $1.8B.
• The Conifer transaction agreed January 27, 2026 brings $1.9B over three annual installments to Tenet — a contract buyout from CommonSpirit Health, not recurring service revenue. Booked through 2026-2028, it will lift CFO by roughly $600M per year before disappearing.

Accrual ratio

FY2024 turns positive at +4.0% — the warning sign — because $2.9B of non-cash gain landed in net income without a corresponding CFO inflow. FY2025 swings sharply negative (-7.3%) as cash earnings outrun GAAP earnings. Together they net out, but the year-by-year pattern is exactly what a forensic test should highlight: large divergence between accrual earnings and cash earnings.

Metric Hygiene

Tenet's non-GAAP framework is reasonable on paper but contains three definitional choices that flatter the headline picture.

Non-GAAP gap and adjusted EBITDA path

The three lines sit on top of each other in FY2024, then fan out in FY2025 — the textbook visual fingerprint of a one-time gain. Adjusted EBITDA tracks the underlying business; GAAP operating income and net income both jumped artificially in 2024.

What to Underwrite Next

The forensic risks around Tenet are real but bounded. They are valuation-relevant, not thesis-breaking, and the cash conversion math is acceptable when normalized. The five highest-value watch items:

1. SEC enforcement matter signaled by the Fuzzy Panda FOIA appeal. The 7(A) exemption response is consistent with an active investigation, not a closed one. Track 8-K filings for Wells notices, settlement disclosures, or required restatement language. Resolution materially upgrades or downgrades this score depending on direction.

2. Conifer cash flow recognition through 2026-2028. Verify the $1.9B is presented as operating cash flow (the natural place for a customer payment) and that management explicitly carves it out in adjusted FCF reconciliation. If presented inside CFO without segregation, treat headline 2026-2028 FCF as overstated by ~$600M annually.

3. 2026 Adjusted EBITDA bridge. Management's claim of 10% core growth depends on three normalizations: $148M out-of-period DPP added back, $40M Conifer one-time stripped out, and $250M PTC headwind absorbed. Watch Q1 2026 effectuation rates on exchange enrollment — Hospital segment is most exposed in Arizona, Michigan and California.

4. Accounting leadership transition. R. Scott Ramsey served as Principal Accounting Officer through April 30, 2026; J. Michael Grooms succeeds May 1. Long-tenured PAO transitions are a common moment for previously deferred adjustments to surface. Watch the FY2026 10-K for any change in critical accounting estimate language, reserve methodology, or revenue recognition disclosures.

5. Goodwill / intangibles trajectory in a soft-volume scenario. Soft assets are 42% of total assets. If 2026 hospital admissions disappoint by more than the company's 1-2% guide, USPI's $11.2B goodwill warrants impairment-test pressure. Specifically watch reporting unit fair value disclosures in the FY2026 10-K.

Signals that would downgrade the grade to Elevated (41-60): SEC enforcement proceeds publicly with a restatement requirement; FY2026 reveals Conifer cash classified ambiguously inside CFO; FY2026 reserve releases or impairment charges exceed the FY24-25 baseline.

Signals that would upgrade the grade to Clean (under 21): Public closure of the SEC matter without action; Conifer cash explicitly carved out of adjusted CFO; FY2026 Adjusted EBITDA delivers in line with guidance with no further normalization items.

Position-sizing implication. This is not a thesis-breaker. The forensic flags justify a valuation haircut of roughly 5-10% on EV/EBITDA versus a clean-balance-sheet peer, and a smaller initial position with active monitoring of the next two earnings releases. The largest risk is single-event — a regulatory action or restatement — rather than a slow erosion of earnings quality. Use Adjusted EBITDA, FCF after NCI, and acquisition-adjusted FCF as the three numbers that matter; ignore GAAP operating income for trend purposes.